• Yıldız Hayran, Nuran Allı, Ümit Akpınar, Ayşe Öktem, Çiğdem Yücel, Esra Fırat Oguz, and Turan Turhan.
• Department of Dermatology, Ankara City Hospital, Ankara, Turkey.
• Int. J. Clin. Pract. 2021 Oct 1; 75 (10): e14545.

IntroductionGalectin-3 is a β-galactoside-binding lectin associated with cellular proliferation, inflammation and angiogenesis, which are the major characteristics of psoriatic skin.ObjectivesTo investigate serum galectin-3 levels in psoriasis patients compared with healthy controls and to study its relationship with disease characteristics.MethodsSeventy-eight patients diagnosed with psoriasis and 78 age- and sex-matched healthy volunteers were included in the study. Serum galectin-3, IL-17, IL-6 and TNF-α levels were measured using Enzyme-linked immunosorbent assay (ELISA).ResultsSerum Galectin-3, IL-17, IL-6 and TNF-α levels were significantly higher in psoriasis patients compared with control group (P < .001, P = .003, P < .001 and P < .001, respectively). A cut-off value of 10 ng/mL for galectin-3 was set after receiver operating characteristic analysis. A serum galectin-3 level >10 ng/mL increased the risk of psoriasis by 14.5 times (95% CI: 6.6-32.3, P < .001) and a serum galectin-3 level >10 ng/mL predicted psoriasis with 83.3% sensitivity and 74.3% specificity. No statistically significant association was observed between serum galectin-3 concentrations and disease characteristics including disease severity, presence of psoriatic arthritis, nail involvement and psoriatic comorbidity. No statistically significant correlation was observed between serum galectin-3 level and serum IL-17, IL-6 and TNF-α levels (all three P values > .05).ConclusionsElevated serum galectin-3 levels in psoriasis patients may indicate a possible role of galectin-3 in pathogenesis of psoriasis.© 2021 John Wiley & Sons Ltd.

9 keywords...

hide…